Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.97)
# 2,995
Out of 4,886 analysts
99
Total ratings
37.04%
Success rate
-7.27%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.71 | +84.50% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $2.40 | +108.33% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $1.77 | +238.98% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $21.42 | +110.08% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $52.25 | +60.77% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $111.06 | -0.95% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $43.51 | -12.65% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $13.91 | +7.84% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $55.79 | -5.00% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $3.94 | +153.81% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $57 → $70 | $36.44 | +92.10% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $2 | $1.70 | +17.65% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.86 | +921.51% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $5.67 | +235.10% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.50 | +500.00% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.36 | +932.49% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $31.32 | +14.94% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $6.61 | +505.14% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.92 | +51.21% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $12.21 | +186.77% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.64 | +599.84% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.31 | +2,190.08% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.10 | +1,718.18% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $2.20 | +354.55% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $5.70 | +215.79% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.53 | +1,533.99% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.36 | -47.92% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.75 | -3.61% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.11 | +35.14% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $9.22 | +2,069.20% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.82 | +501.37% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.60 | +3,650.00% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $3.04 | +492.11% | 3 | Apr 7, 2020 |
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.71
Upside: +84.50%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $2.40
Upside: +108.33%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $1.77
Upside: +238.98%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $21.42
Upside: +110.08%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $52.25
Upside: +60.77%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $111.06
Upside: -0.95%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $43.51
Upside: -12.65%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.91
Upside: +7.84%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $55.79
Upside: -5.00%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $3.94
Upside: +153.81%
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $36.44
Upside: +92.10%
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.70
Upside: +17.65%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.86
Upside: +921.51%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $5.67
Upside: +235.10%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.50
Upside: +500.00%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.36
Upside: +932.49%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $31.32
Upside: +14.94%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $6.61
Upside: +505.14%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.92
Upside: +51.21%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $12.21
Upside: +186.77%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.64
Upside: +599.84%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.31
Upside: +2,190.08%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.10
Upside: +1,718.18%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $2.20
Upside: +354.55%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $5.70
Upside: +215.79%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.53
Upside: +1,533.99%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.36
Upside: -47.92%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $20.75
Upside: -3.61%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.11
Upside: +35.14%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $9.22
Upside: +2,069.20%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $5.82
Upside: +501.37%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.60
Upside: +3,650.00%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $3.04
Upside: +492.11%